Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Status Completed

Clinical Trial Summary

The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer.

MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01169649
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	Phase 2
Start date	July 2010
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00557596` - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT00707278` - Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma	Phase 1
Recruiting	`NCT03348319` - Is There a Pancreatic Segmentation Based on the Pancreatic Duct Branching?
Terminated	`NCT02244164` - Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.	N/A
Recruiting	`NCT02979483` - Management of Symptomatic Advanced Pancreatic Adenocarcinoma	N/A
Completed	`NCT00497224` - Phase II Trial of Erlotinib in Advanced Pancreatic Cancer	Phase 2
Terminated	`NCT04764396` - Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies	N/A
Completed	`NCT04935216` - Predictors of Postoperative Complications and Readmissions in Laparoscopic Pancreas Resection
Completed	`NCT00936104` - Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)	N/A
Completed	`NCT00918853` - Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas	N/A
Available	`NCT01786850` - Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer	N/A